FindMyKOL
Clinical trialNCT02353078CompletedPhase Early 1Interventional

The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis

NCT02353078 is a phase early 1 interventional trial sponsored by Mayo Clinic. As of 21 Nov 2026, it is completed. It studies Sucralfate in Eosinophilic Esophagitis. The registry lists an enrollment of 3 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2015 and a primary completion date of 31 Dec 2016.

SponsorMayo Clinic →Enrollment3Eosinophilic Esophagitis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02353078
FieldValue
Registry IDNCT02353078
StatusCompleted
PhasePhase Early 1
Study typeInterventional trial
Lead sponsorMayo Clinic
Enrollment3
Registered sites1
Countries1
ConditionsEosinophilic Esophagitis
DrugsSucralfate
Start31 Jan 2015
Primary completion31 Dec 2016
Study completion31 Dec 2016
Last update posted11 Oct 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Could Sucralfate be a non-steriodal treatment option for patients with Eosinophilic esophagitis?

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Minnesota, United States1 site
  • Mayo Clinic in Rochester

    Rochester

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesota: 1 siteMN1WisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02353078

Each answer restates registry values shown on this page.

What is NCT02353078?

NCT02353078 is a phase early 1 interventional trial sponsored by Mayo Clinic. It studies Sucralfate in Eosinophilic Esophagitis.

Who leads NCT02353078?

The registry names David Katzka, MD (principal investigator, Mayo Clinic) as the overall official.

Where does NCT02353078 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02353078 study?

The registered drug and biological interventions are Sucralfate.

When did NCT02353078 end?

The registry lists a primary completion date of 31 Dec 2016 and a study completion date of 31 Dec 2016. The sponsor last updated the record on 11 Oct 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.